Administrative
Resolution No. (62) of 2020
Approving the Charges for Laboratory
Tests Conducted at
the
Dubai
Health Authority Laboratories[1]
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
The Director General of the Dubai Health
Authority,
After perusal of:
Law
No. (14) of 2009 Concerning the Pricing of Government Services in the Emirate
of Dubai and its amendments;
Law
No. (1) of 2016 Concerning the Financial Regulations of the Government of
Dubai;
Law
No. (6) of 2018 Concerning the Dubai Health Authority (the “DHA");
Decree
No. (9) of 2012 Approving a Pricing Method for Dubai Health Authority Services;
Decree
No. (17) of 2018 Establishing the Corporations Affiliated to the Dubai Health
Authority and Determining their Functions;
Decree
No. (18) of 2018 Appointing the Director General of the Dubai Health Authority;
Executive
Council Resolution No. (18) of 2018 Approving the Organisational Structure of
the Dubai Health Authority;
Administrative
Resolution No. (148) of 2014 Concerning Health Service Fees; and
The
Department of Finance approval
of the charges
for new laboratory tests, dated 28 June
2020, Ref. DOF/OUT/2020/0001504,
Does hereby issue this Resolution.
Pursuant
to this Resolution, the charges for laboratory tests conducted at the DHA
laboratories, as stated in the Schedule attached hereto, are approved.
All
Organisational Units of the DHA, each within its own powers, must take the
necessary action to implement this Resolution.
Any
provision in any other administrative resolution will be repealed to the extent
that it contradicts the provisions of this Resolution.
This
Resolution comes into force on the day on which it is issued, and will be
published in the Official Gazette.
Humaid Al Qatami
Director General
Dubai Health Authority
Issued in Dubai on 6 July 2020
Corresponding to 15
Thu al-Qidah 1441 A.H.
Charges for
Laboratory Tests Conducted at the
Dubai Health
Authority Laboratories
|
SN |
Service Code |
Service Description |
Proposed Price in Dirhams |
|
1 |
81214 |
BRCA1
(breast cancer 1) (e.g. hereditary breast and ovarian cancer) gene analysis;
full sequence analysis and common duplication/deletion variants (i.e. exon 13
del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon
8-9 del 7.1kb) |
6,490.00 |
|
2 |
81408 |
Molecular
pathology procedure, Level 9 (e.g. analysis of > 50 exons in a single gene
by DNA sequence analysis) FBN1 (fibrillin 1) (e.g. Marfan syndrome), full
gene sequence NF1 (neurofibromin 1) (e.g. neurofibromatosis, type 1), full
gene sequence RYR1 (ryanodine receptor 1, skeletal) (e.g. malignant
hyperthermia), full gene sequence VWF (von Willebrand factor) (e.g. von
Willebrand disease types 1 and 3), full gene sequence |
6,511.00 |
|
3 |
81407 |
Molecular
pathology procedure, Level 8 (e.g. analysis of 26-50 exons by DNA sequence
analysis, mutation scanning or duplication/deletion variants of > 50
exons, sequence analysis of multiple genes on 1 platform) SCN1A (sodium
channel, voltage-gated, type 1, alpha subunit) (e.g. generalized epilepsy with
febrile seizures), full gene sequence |
8,545.00 |
|
4 |
2008127 |
ANTI
SACCHAROMYCES CEREVI. ABS |
174.00 |
|
5 |
2090018 |
Aicardi-Goutières
syndrome (NGS) |
6,830.00 |
|
6 |
2090019 |
Aldosterone-Sensitive
Distal Nephron (NGS) |
6,830.00 |
|
7 |
2090020 |
Alport
syndrome (NGS) |
6,830.00 |
|
8 |
2090021 |
Amyotrophic
lateral sclerosis (ALS) (NGS) |
10,430.00 |
|
9 |
2090022 |
Angelman
-like syndrome (NGS) |
8,630.00 |
|
10 |
2090023 |
Aortopathy
(NGS) |
10,430.00 |
|
11 |
2090024 |
Cardiomyopathy
(ARVD/ARVC)/Arrhythmogenic right ventricular dysplasia (NGS) |
8,630.00 |
|
12 |
2090025 |
Ataxia
(NGS) |
10,430.00 |
|
13 |
2090026 |
Ataxic
polyneuropathies (NGS) |
10,430.00 |
|
14 |
2090027 |
Auditory
neuropathy (NGS) |
6,830.00 |
|
15 |
2090028 |
Burkitt
lymphoma (NGS) |
6,830.00 |
|
16 |
2090029 |
C3-Glomerulopathies
(C3G) (NGS) |
8,630.00 |
|
17 |
2090030 |
Cardiofaciocutaneous
syndrome (NGS) |
8,630.00 |
|
18 |
2090031 |
Cardiomyopathy,
dilated (NGS) |
10,430.00 |
|
19 |
2090032 |
CFHR5-Nephropathy
(NGS) |
8,630.00 |
|
20 |
2090033 |
Chondrodysplasia
punctate (NGS) |
6,830.00 |
|
21 |
2090034 |
Congenital
disorders of glycosylation (CDG) (NGS) |
10,430.00 |
|
22 |
2090035 |
Congenital
heart defects (NGS) |
10,430.00 |
|
23 |
2090036 |
Corneal
dystrophies (NGS) |
8,630.00 |
|
24 |
2090038 |
Craniosynostosis
syndromes (NGS) |
10430.00 |
|
25 |
2090039 |
Cutaneous
T-cell lymphoma (NGS) |
6,830.00 |
|
26 |
2090040 |
Cystinuria
(NGS) |
6,830.00 |
|
27 |
2090041 |
Dent
syndrome (NGS) |
6,830.00 |
|
28 |
2090042 |
Diabetes
insipidus (NGS) |
6,830.00 |
|
29 |
2090043 |
Diabetes
mellitus,monogenic (NGS) |
10,430.00 |
|
30 |
2090044 |
Diffuse
large B-cell lymphoma (NGS) |
8,630.00 |
|
31 |
2090045 |
Disorders
of sex development (DSD (NGS) |
10,430.00 |
|
32 |
2090046 |
Dyskeratosis
congenita (NGS) |
8,630.00 |
|
33 |
2090047 |
Dystonie
(NGS) |
10,430.00 |
|
34 |
2090048 |
Ectodermal
dysplasia (NGS) |
10,430.00 |
|
35 |
2090049 |
Ellis-van-Crefeld
syndrome (NGS) |
7,280.00 |
|
36 |
2090050 |
Epidermolysis
bullosa (NGS) |
8,630.00 |
|
37 |
2090051 |
Epilepsy
(NGS) |
10,430.00 |
|
38 |
2090052 |
Epilepsy,
metabolic (NGS) |
10430.00 |
|
39 |
2090053 |
Fanconi
anemia (NGS) |
8,630.00 |
|
40 |
2090054 |
Fatty
acid oxidation disorders (NGS) |
8,630.00 |
|
41 |
2090055 |
Follicular
lymphoma (NGS) |
6,830.00 |
|
42 |
2090056 |
Frontotemporal
dementia (NGS) |
8,630.00 |
|
43 |
2090057 |
Glucocorticoid
Deficiency (NGS) |
6,830.00 |
|
44 |
2090058 |
Familial
Gluconeogenesis (NGS) |
6,830.00 |
|
45 |
2090059 |
Glycogen
Storage Disease (NGS) |
7,223.00 |
|
46 |
2090060 |
Growth
Hormone Deficiency (NGS) |
10,430.00 |
|
47 |
2090062 |
Hereditary
sensory and autonomic neuropathy (HSAN) (NGS) |
8,630.00 |
|
48 |
2090063 |
Hermansky-Pudlak
syndrome (NGS) |
6,830.00 |
|
49 |
2090064 |
Holoprosencephaly
Hyperekplexia (NGS) |
6,830.00 |
|
50 |
2090065 |
Hyperoxaluria
Hypertriglyceridemia (NGS) |
6,830.00 |
|
51 |
2090066 |
Familial
Hypoglycemia (NGS) |
10,430.00 |
|
52 |
2090067 |
Hypogonadotropic
hypogonadism (NGS) |
8,630.00 |
|
53 |
2090068 |
Hypophosphatemic
rickets/Phosphate diabetes (NGS) |
8,630.00 |
|
54 |
2090069 |
Ichthyosis
and related disorders of cornification (NGS) |
10,430.00 |
|
55 |
2090070 |
Cholestasis,
progressive familial intrahepatic (NGS) |
6,830.00 |
|
56 |
2090071 |
Kartagener
syndrome (NGS) |
10,430.00 |
|
57 |
2090072 |
Ketogenesis
disorder (NGS) |
6,830.00 |
|
58 |
2090073 |
Ketolysis
disorder (NGS) |
6,830.00 |
|
59 |
2090074 |
Left
ventricular noncompaction (NGS) |
6,830.00 |
|
60 |
2090075 |
Leigh
syndrome (NGS) |
10,430.00 |
|
61 |
2090076 |
Acute
Myeloid Leukemia (NGS) |
8,630.00 |
|
62 |
2090077 |
Atypical
Chronic Myeloid Leukemia (NGS) |
6,830.00 |
|
63 |
2090078 |
Chronic
Myelomonocytic Leukemia (NGS) |
6,830.00 |
|
64 |
2090079 |
Chronic
Neuthrophilic Leukemia (NGS) |
6,830.00 |
|
65 |
2090080 |
Leukodystrophy
(NGS) |
10,430.00 |
|
66 |
2090081 |
T-cell
acute lymphoblastic Leukemia (NGS) |
8,630.00 |
|
67 |
2090082 |
Limb-girdle
muscular dystrophy (LGMD) (NGS) |
10,430.00 |
|
68 |
2090083 |
Lissencephaly
(NGS) |
10,430.00 |
|
69 |
2090084 |
Loeys-Dietz
syndrome (NGS) |
6,830.00 |
|
70 |
2090085 |
Lysosomal
disorders (NGS) |
10,430.00 |
|
71 |
2090086 |
Macrocephaly
(NGS) |
10,430.00 |
|
72 |
2090087 |
Malignant
Hyperthermia (NGS) |
6,830.00 |
|
73 |
2090088 |
Mantle
Cell Lymphoma (NGS) |
6,830.00 |
|
74 |
2090089 |
Medullary
Cystic Kidney Disease (MCKD) (NGS) |
6,830.00 |
|
75 |
2090090 |
Micromelic
Dysplasia (NGS) |
10,430.00 |
|
76 |
2090091 |
Metaphyseal
dysplasia (NGS) |
6,830.00 |
|
77 |
2090092 |
Mitochondrial
encephalopathy (NGS) |
10,430.00 |
|
78 |
2090093 |
Morbus
Waldenström (NGS) |
6,830.00 |
|
79 |
2090094 |
mtDNA
Depletion/Integrity panel (NGS) |
6,830.00 |
|
80 |
2090095 |
Mucopolysaccharidosis
(NGS) |
8,630.00 |
|
81 |
2090096 |
Multiple
Epiphyseal Dysplasia and Pseudoachondroplasia (NGS) |
6,830.00 |
|
82 |
2090097 |
Multiple
Myeloma (NGS) |
6,830.00 |
|
83 |
2090098 |
Muscular
Dystrophies,Congenital (NGS) |
10,430.00 |
|
84 |
2090099 |
Myasthenic
Syndrome, Congenital (NGS) |
8,630.00 |
|
85 |
2090100 |
Myelodysplastic
syndrome (NGS) |
10,430.00 |
|
86 |
2090101 |
Myopathy,
Distal (NGS) |
10,430.00 |
|
87 |
2090103 |
Myotonia
(NGS) |
6,830.00 |
|
88 |
2090104 |
Nephrocalcinosis
(NGS) |
10,430.00 |
|
89 |
2090105 |
Neurodegeneration
with Brain Iron Accumulation (NBIA) (NGS) |
8,630.00 |
|
90 |
2090106 |
Neurofibromatosis
(NF) (NGS) |
6,830.00 |
|
91 |
2090107 |
Neuronal
Migration Disorder (NGS) |
10,430.00 |
|
92 |
2090108 |
NK/T-Cell
Lymphoma (NGS) |
6,830.00 |
|
93 |
2090109 |
Nystagmus
(NGS) |
6,830.00 |
|
94 |
2090110 |
Obesity
(NGS) |
10,430.00 |
|
95 |
2090112 |
Pancreas
Carcinoma (NGS) |
8,630.00 |
|
96 |
2090113 |
Pancreatitis,
Chronic (NGS) |
6,830.00 |
|
97 |
2090114 |
Parkinson
Disease (NGS) |
13,966.00 |
|
98 |
2090115 |
Pena-Shokeir
Syndrome (NGS) |
8,630.00 |
|
99 |
2090116 |
Pendred
Syndrome (NGS) |
8,630.00 |
|
100 |
2090117 |
Periodic
Fever Syndromes/Autoinflammation (NGS) |
10,430.00 |
|
101 |
2090118 |
Peripheral
T-Cell Lymphoma (NGS) |
6,830.00 |
|
102 |
2090119 |
Perrault
Syndrome (NGS) |
6,830.00 |
|
103 |
2090120 |
Polymicrogyria
(NGS) |
8,630.00 |
|
104 |
2090121 |
Pontocerebellar
Hypoplasia (NGS) |
6,830.00 |
|
105 |
2090122 |
Porphyria
(NGS) |
6,830.00 |
|
106 |
2090123 |
Progeria
Syndromes (NGS) |
8,630.00 |
|
107 |
2090124 |
Progressive
External Ophthalmoplegia (PEO) (NGS) |
8,630.00 |
|
108 |
2090125 |
Prostate
Cancer (NGS) |
10,430.00 |
|
109 |
2090126 |
Pulmonary
Hypertension (NGS) |
6,830.00 |
|
110 |
2090127 |
Pyruvate
Dehydrogenase Deficiency (NGS) |
6,830.00 |
|
111 |
2090128 |
Rasopathies
(NGS) |
8,630.00 |
|
112 |
2090129 |
Refsum
Syndrome (NGS) |
8,630.00 |
|
113 |
2090131 |
Renal
Carcinoma (NGS) |
8,630.00 |
|
114 |
2090132 |
Retinitis
Pigmentosa (NGS) |
10,430.00 |
|
115 |
2090133 |
Retinoblastoma
(NGS) |
6,830.00 |
|
116 |
2090134 |
SANDD
Syndrome (NGS) |
6,830.00 |
|
117 |
2090135 |
Schizencephaly
(NGS) |
6,830.00 |
|
118 |
2090136 |
Short
Stature (NGS) |
8,630.00 |
|
119 |
2090137 |
Skeletal
Dyplasia with Abnormal Bone Density/Mineralisation (NGS) |
8,630.00 |
|
120 |
2090138 |
Spastic
Paraplegia (NGS) |
10,430.00 |
|
121 |
2090139 |
Spinal
Muscular Atrophy, Distal (NGS) |
10,430.00 |
|
122 |
2090140 |
Splenic
Marginal Zone Lymphoma (NGS) |
6,830.00 |
|
123 |
2090141 |
Spondylometaphyseal
Dysplasia and Spondyloepiphyseal Dysplasia (NGS) |
10,430.00 |
|
124 |
2090142 |
Stargardt
Disease (NGS) |
6,830.00 |
|
125 |
2090143 |
Stickler
Syndrome (NGS) |
6,830.00 |
|
126 |
2090145 |
Thrombotic
Microangiopathy (TMA) (NGS) |
8,630.00 |
|
127 |
2090146 |
Thrombotic
Thrombocytopenic Purpura (TTP) (NGS) |
8,630.00 |
|
128 |
2090147 |
Treacher
Collins Syndrome (NGS) |
6,830.00 |
|
129 |
2090148 |
Walker-Warburg
Syndrome (NGS) |
8,630.00 |
|
130 |
2090149 |
Warburg-Micro
Syndrome (NGS) |
10,430.00 |
|
131 |
2090150 |
Xanthinuria
(NGS) |
6,830.00 |
|
132 |
2090151 |
Xeroderma
Pigmentosum (NGS) |
6,830.00 |
|
133 |
2090152 |
X-linked
mental retardation (NGS) |
10,430.00 |
|
134 |
2090154 |
Albinism,
Oculocutaneous (MC1R) |
1,655.00 |
|
135 |
2090155 |
Alpha-1-Antitrypsin
Deficiency (SERPINA1) |
980.00 |
|
136 |
2090156 |
Alpha-Thalassemia
(HBA, HBA2, sequencing + MLPA) |
2,780.00 |
|
137 |
2090157 |
Pulmonary
Alveolar Microlithiasis (SLC34A2) |
3,680.00 |
|
138 |
2090158 |
Amyloidosis,
Hereditary, Transthyretin-related (TTR, stage 1) |
980.00 |
|
139 |
2090159 |
Amyloidosis,
Hereditary, Transthyretin-related (TTR, stage 2) |
1,295.00 |
|
140 |
2090160 |
Arthrogryposis
(TNNI2) |
2,105.00 |
|
141 |
2090161 |
Arts
Syndrome (PRPS1) |
2,330.00 |
|
142 |
2090162 |
Ataxia
Teleangiectasia (ATM) |
6,830.00 |
|
143 |
2090163 |
Ataxia
Teleangiectasia (ATM, MLPA) |
1880.00 |
|
144 |
2090164 |
Beta-Propeller
Protein-Associated Neurodegeneration (WDR45) |
2,555.00 |
|
145 |
2090166 |
Blepharophimosis
(FOXL2) |
980.00 |
|
146 |
2090167 |
Hypertension
and Brachydactyly Syndrome (PDE3A) |
5,399.00 |
|
147 |
2090169 |
Coenzyme
Q10 Deficiency (NGS) |
8,630.00 |
|
148 |
2090170 |
Cohesinopathies
(e.g. Cornelia de Lange Syndrome) (NGS) |
6,830.00 |
|
149 |
2090171 |
Cowden
Syndrome 3 (NGS) |
6,830.00 |
|
150 |
2090172 |
CTNNB1-Associated
Diseases (CTNNB1) |
3,905.00 |
|
151 |
2090173 |
Donnai-Barrow
Syndrome (LRP2) |
6,830.00 |
|
152 |
2090174 |
Dravet
Syndrome (GABRG2) |
3455.00 |
|
153 |
2090176 |
Ellis-Van-Creveld
Syndrome (EVC, EVC2, MLPA) |
1,880.00 |
|
154 |
2090177 |
Encephalopathy
Syndrome, Lethal Neonatal Spasticity-Epileptic (BRAT1) |
5,030.00 |
|
155 |
2090178 |
Epileptic
Encephalopathy (WWOX) |
3,005.00 |
|
156 |
2090180 |
Fleck
Retina, Familial Benign (PLA2G5) |
1,565.00 |
|
157 |
2090181 |
Exudative
Vitreoretinopathy (LRP5) |
6,830.00 |
|
158 |
2090182 |
Exudative
Vitreoretinopathy Type 1 (FZD4) |
1,115.00 |
|
159 |
2090183 |
Familial
Isolated Arrhythmogenic Ventricular Dysplasia (PKP2) |
5,317.00 |
|
160 |
2090184 |
X-Linked
Intellectual Disability (OPHN1) |
4,580.00 |
|
161 |
2090185 |
Limb-Girdle
Muscular Dystrophy Type 2D (SGCA) |
3,157.00 |
|
162 |
2090186 |
Glioma
(POT1) (NGS) |
4,580.00 |
|
163 |
2090187 |
Hemolytic-Uremic
Syndrome, Atypical (AHUS3/CFI) |
3,110.00 |
|
164 |
2090188 |
Hemolytic-Uremic
Syndrome, Atypical (AHUS5/C3) |
5,930.00 |
|
165 |
2090189 |
Hemolytic-Uremic
Syndrome, Atypical (AHUS7/DGKE) |
3,005.00 |
|
166 |
2090190 |
Hermansky-Pudlak
syndrome 1 (HPS1) |
5,030.00 |
|
167 |
2090191 |
Hermansky-Pudlak
Syndrome 3 (HPS3) |
5,030.00 |
|
168 |
2090192 |
Hermansky
Pudlak Syndrome 5 (HPS5) |
5,030.00 |
|
169 |
2090193 |
Hermansky-Pudlak
Syndrome 6 (HPS6) |
2,371.00 |
|
170 |
2090194 |
Hermansky-Pudlak
Syndrome 8 (HPS8/BLOC1S3) |
980.00 |
|
171 |
2090195 |
HIV
Infection, Susceptibility/Resistance to (CCR5) |
980.00 |
|
172 |
2090196 |
Corneal
Dystrophy (SLC4A11) |
5,480.00 |
|
173 |
2090197 |
Hyper-IgE
Syndrome-NGS (NGS) |
6,830.00 |
|
174 |
2090198 |
Hyperlipoproteinemia
(APOA5) (NGS) |
6,830.00 |
|
175 |
2090199 |
Hypophosphatemia
with Hypercalciuria (SLC34A3) |
2,555.00 |
|
176 |
2090200 |
Hypophosphatemia
with Nephrolithiasis or Osteoporosis (SLC34A1) |
4,008.00 |
|
177 |
2090201 |
Hypophosphatemic
Rickets, Autosomal Dominant (FGF23, MLPA) |
1,913.00 |
|
178 |
2090202 |
Imerslund-Grasbeck
Syndrome (AMN) |
3,095.00 |
|
179 |
2090203 |
Jalili
Syndrome (cone-rod retinal dystrophy and amelogenesis imperfecta) (CNNM4) |
3,026.00 |
|
180 |
2090204 |
Jervell-
and Lange-Nielsen Syndrome (NGS) |
6,830.00 |
|
181 |
2090205 |
Joubert
Syndrome (POC1B) |
3,905.00 |
|
182 |
2090206 |
Campomelic
Dysplasia (SOX9, MLPA) |
1,880.00 |
|
183 |
2090207 |
Cataract
Syndrome (CRYAA) |
1,880.00 |
|
184 |
2090208 |
Cataract
14, Multiple Types (GJA3) |
980.00 |
|
185 |
2090210 |
Lathosterolosis
(SC5DL) |
3,680.00 |
|
186 |
2090211 |
Legius
syndrome (SPRED1) |
2,465.00 |
|
187 |
2090213 |
Lesch-Nyhan
syndrome (HPRT1, MLPA) |
2,371.00 |
|
188 |
2090215 |
Lujan-Fryns
Syndrome (MED12) (NGS) |
6,830.00 |
|
189 |
2090216 |
Mayer-Rokitansky-Küster-Hauser
Syndrome (WNT4) |
2,015.00 |
|
190 |
2090217 |
Megalencephaly-Capillary
Malformation-Polymicrogyria Syndrome, Somatic (PIK3CA ) |
5,930.00 |
|
191 |
2090218 |
Microcephaly
(ASPM) |
6,830.00 |
|
192 |
2090219 |
Microcephaly
(KIF11) |
4,130.00 |
|
193 |
2090220 |
Microcephaly
(PCNT) |
10,430.00 |
|
194 |
2090221 |
Microcephaly
(RBBP8) |
5,930.00 |
|
195 |
2090222 |
Microcephaly
(SLC25A19) |
2,555.00 |
|
196 |
2090223 |
Mitochondrial
DNA Depletion Syndrome (DGUOK) |
2,830.00 |
|
197 |
2090224 |
Wilson
Disease (ATP7B, Stage 3, MLPA) |
1,880.00 |
|
198 |
2090226 |
Myotonia
Congenita Type Becker/Thomsen (CLCN1, MLPA) |
2,155.00 |
|
199 |
2090227 |
Nephronophthisis
(NPHP4) |
5,930.00 |
|
200 |
2090228 |
Nephronophthisis-like
Nephropathy (NPHPL1/XPNPEP3) |
3,353.00 |
|
201 |
2090230 |
Nephrotic
Syndrome (WDR73) |
2,465.00 |
|
202 |
2090231 |
Retinal
Dystrophy (RGS9BP) |
980.00 |
|
203 |
2090232 |
Hereditary
Sensory and Autonomic Neuropathy Type 5 (NGF) |
1,295.00 |
|
204 |
2090233 |
Noonan-like
Syndrome with Loose Anagen Hair (SHOC2) |
3,095.00 |
|
205 |
2090234 |
Osteopathia
Striata, Cranial Sclerosis (AMER1/WTX) |
2,465.00 |
|
206 |
2090235 |
Paralysis,
Thyrotoxic Periodic (KCNJ18) |
1,295.00 |
|
207 |
2090236 |
Perrault
Syndrome (CLPP) |
1,880.00 |
|
208 |
2090237 |
Perrault
Syndrome (LARS2) |
4,662.00 |
|
209 |
2090238 |
Polycystic
Liver Disease (GANAB) |
6,155.00 |
|
210 |
2090240 |
Retinol
Dystrophy, Iris coloboma, and Comedogenic Acne Syndrome (RBP4) |
1,655.00 |
|
211 |
2090241 |
Retinitis
Pigmentosa (IMPG2) |
6,830.00 |
|
212 |
2090242 |
Retinitis
Pigmentosa (LRAT) |
1,115.00 |
|
213 |
2090243 |
Retinitis
Pigmentosa (NR2E3) |
3,095.00 |
|
214 |
2090244 |
Rett-like
syndrome (NTNG1, MLPA) |
1,880.00 |
|
215 |
2090245 |
Rett-like
syndrome (NTNG1, Seq.) |
2,195.00 |
|
216 |
2090246 |
Robinow
Syndrome (WNT5A) |
4,355.00 |
|
217 |
2090247 |
Deafness
(GPSM2) |
4,580.00 |
|
218 |
2090248 |
Very
Long Chain Acyl-CoA Dehydrogenase Deficiency (ACADVL) |
6,380.00 |
|
219 |
2090249 |
Simpson-Golabi-Behmel
Syndrome (GPC3) (Testicular Feminization Syndrome) |
3,353.00 |
|
220 |
2090251 |
TARP
Syndrome (RBM10) |
5,930.00 |
|
221 |
2090254 |
Hyperphosphatemic
Tumoral Calcinosis, Familial (GALNT3) |
5,534.00 |
|
222 |
2090255 |
Vasculopathy,
ADA2 Deficiency (CECR1) |
3,005.00 |
|
223 |
2090256 |
Wolman
Disease (LIPA) |
3,005.00 |
|
224 |
2090257 |
Cone-Rod
Dystrophy (CTNNA1) |
4,355.00 |
|
225 |
2090258 |
Congenital
Adrenal Hyperplasia (NGS) |
8,630.00 |
|
226 |
2090259 |
Lysosomal
Perioxisomal Disorders NGS |
10,430.00 |
|
227 |
2090260 |
CYP21A2
Deletion & Duplication (MLPA) |
1,880.00 |
|
228 |
2090261 |
Microarray
CGH 180 K Amniotic Fluid/CVS |
6,750.00 |
|
229 |
2090262 |
PTEN
Gene Amniotic fluid/CVS |
2,925.00 |
|
230 |
2090263 |
Skeletal
Dysplasia and Pena Shokeir Syndrome |
8,630.00 |
|
231 |
2090264 |
Methylation
Test Russel Siver Syndrome |
1,880.00 |
|
232 |
2090265 |
Ichthyoses
and Related Disorder panels |
10,430.00 |
|
233 |
2090266 |
Heteroxy
and Situs Inversion Panel |
10,430.00 |
|
234 |
2090267 |
Multi
Gene Panel- Mitochondrial |
10,430.00 |
|
235 |
2090268 |
Sister
Chromatid Exchange for Bloom Syndrome. |
1,871.00 |
|
236 |
2090269 |
Breast
Cancer Mutigene Panel-NGS |
8,630.00 |
|
237 |
2090270 |
Medium
Chain Acyl CoA Deficiecy |
3,905.00 |
|
238 |
2090271 |
Gastrointestinal
Atresia Panel |
6,626.00 |
|
239 |
2090272 |
KGB
Syndrome |
3,680.00 |
|
240 |
2090273 |
Neurofascins
Abs. (140 & 155) |
1,954.00 |
|
241 |
2090274 |
Contactin-
1 (CASPR1) |
1,138.00 |
|
242 |
2090275 |
Amlodipine |
418.00 |
|
243 |
2090276 |
Beta
HCG(CSF) |
454.00 |
|
244 |
2090277 |
Alpha
Feto protein (AFP) (CSF) |
205.00 |
|
245 |
2090278 |
HIV
Viral load(CSF) |
945.00 |
|
246 |
2090279 |
5
Methyl Tetra Hydro folate(CSF) |
1,221.00 |
|
247 |
2090280 |
Pregnanacy
Associated Plasma Protein(PAPP-A) |
305.00 |
|
248 |
2090281 |
Rituximab
Neutralizing Abs |
2,905.00 |
|
249 |
2090282 |
Omega
6 Fatty Acids Screen |
306.00 |
|
250 |
2090283 |
Chlamydia
Trachomatis IgA & IgG ABS |
251.00 |
|
251 |
2090284 |
Chlamydia
Pneumonia IgM & IgG ABS |
251.00 |
|
252 |
2090285 |
Zika
Virus IgG/IgM ABS |
305.00 |
|
253 |
2090286 |
Entero
Virus RNA PCR |
741.00 |
|
254 |
2090287 |
Legionella
Culture Specimen |
162.00 |
|
255 |
2090288 |
Porphyrin |
251.00 |
|
256 |
2090289 |
Porphobilinogen |
251.00 |
|
257 |
2090290 |
Pseudomonas
Aeruginosa Abs. |
445.00 |
|
258 |
2090291 |
Oncotype
DX (21 GENES) |
22,080.00 |
|
259 |
2090292 |
Iodine
Urine |
113.00 |
|
260 |
2090293 |
Cytomegalovirus
PCR CSF |
233.00 |
|
261 |
2090294 |
Chickengunya
Virus RNA PCR |
395.00 |
|
262 |
2090295 |
Dihydropteridine
Reductase (DHPR) Activity |
305.00 |
|
263 |
2090296 |
Fibroblast
Growth Factor 23 Level |
180.00 |
©2020 The Supreme
Legislation Committee in the Emirate of Dubai
[1]Every effort has been made to produce an
accurate and complete English version of this legislation. However, for the
purpose of its interpretation and application, reference must be made to the
original Arabic text. In case of conflict, the Arabic text will prevail.